DSP: Phase 1/2 DSP-5336 in Acute Leukemia

DSP: Phase 1/2 DSP-5336 in Acute Leukemia

Es posible que algunos contenidos no estén disponibles en español.

Purpose of this Study

We are doing this study to find out how well an experimental drug called DSP-5336 (the study drug) works in people with AML or ALL.

Who Can Participate?

Eligibility

Adults ages 18+ who:
  • Are diagnosed with Relapsed or Refractory AML or ALL
  • Have a confirmed KMT2A (MLL)-fusion or NPM1 mutation
  • Have acceptable organ function
For more information about who can join this study, please contact the study team at 919-660-2077.

What is Involved?

Description

If you choose to join this study, you will go through a screening period to find out if you are eligible. During this screening period, you will:
  • Have a physical exam
  • Have a heart scan (ECG)
  • Have blood draws
After the screening period, this study is divided into 2 parts. In Part 1, you will be assigned to either:
  • Arm A (not taking a type of antifungal treatment); OR
  • Arm B (you are taking a type of antifungal treatment)
In Part 2, you will be assigned to either:
  • Arm A [R/R AML with Mixed Lineage Leukemia that is rearranged (MLLr AML)]; OR
  • Arm B [R/R leukemia that has the Nucleophosmin 1 gene mutated (NPM1)]
The study drug will be taken by mouth twice daily. Once you stop taking the study drug, you will enter a follow-up period. The study team will call you approximately every 3 months to see how you are feeling during this period.

Study Details

Full Title

A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP-5336 in Adult Acute Leukemia Patients with and without Mixed Lineage Leukemia (MLL)-rearrangement or Nucleophosmin 1 (NPM1) Mutation

Principal Investigator

Harry
Erba

Protocol Number

PRO00109316

NCT ID

NCT04988555

Phase

I/II

Enrollment Status

Open to Enrollment
ClinicalTrials.gov